Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review.

ABSTRACT:

Background

A large proportion of patients eventually experience disease progression despite treatment with immune checkpoint inhibitors (ICIs), but subsequent treatment options are limited for this population. Retreatment with the same or different types of ICIs is a possible strategy, but the clinical efficacy and safety data are limited. This systematic review aims to evaluate the efficacy and safety of ICIs retreatment in patients with solid tumors after disease progression to previous ICIs.

Methods

We searched MEDLINE, EMBASE, the Cochrane Library, and major meeting libraries for prospective studies. The primary outcomes included the objective response rate (ORR), disease control rate (DCR), median overall survival (mOS), and the incidence of grade ⩾3 immune-related adve

SUBMITTER: Yang K 

PROVIDER: S-EPMC7705192 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature